Fundacion Onkologikoa Fundazioa

Donostia 18 trials 6 recruiting

18 Registered trials

6 Currently recruiting

Organisation

Fundacion Onkologikoa Fundazioa

Location

Donostia, Spain

Identifier

ORG-100044928

Address

Pasealeku Doct. Begiristain 121, 20014, Spain

Departments

Medical Oncology
ncology
Oncología
Oncología Médica
Oncology
Onkologikoa

Clinical trials at this site (18)

Search interface

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting

2024-513375-40-00 Melanoma 4 2025-05-16
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination … Recruiting

2024-514746-36-00 Selected tumor indications that are known to express FA 1 2022-10-20
Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting

2023-507119-36-00 Malignant melanoma of the skin in patients with locally 5 2022-05-09
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Clinical Trial to compare subcutaneous pembrolizumab given with hyaluronidase to intravenous pembrolizumab in patients with newly diagnosed … Ended

2024-513165-39-00 Participants With Metastatic Non-small Cell Lung Cancer 5 2024-11-11
PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED… Ended

2024-512963-30-00 Locally advanced or unresectable PIK3CA and/or PTENalte 4 2023-05-24
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended

2024-510913-13-00 Previously Untreated Metastatic or Unresectable Melanom 10 2018-05-18
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended

2024-515368-29-00 patients with node positive breast cancer who do not ha 5 2012-09-20
Clinical trial of MK-7648A in adults and children with skin cancer Ended

2022-501417-31-01 melanoma 5 2023-08-01
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended

2024-512052-38-00 Advanced triple negative breast cancer 9 2021-12-02
Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended

2024-511295-33-00 Study to evaluate the effect of metformin in the preven 4 2020-08-13
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 5 2019-03-04
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18